MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals Inc. is projected to experience significant revenue growth, with core business revenues anticipated to exceed $1 billion, bolstered by Livmarli's expected sales reaching over $800 million by 2031. The company is poised for a 69% year-over-year growth in Livmarli sales for FY25, driven by steady increases in new patient diagnoses for Alagille syndrome and strong growth in the adult PFIC market, alongside a 31% annual increase in its bile acid portfolio attributed to heightened awareness. Additionally, the successful expansion of indications for Livmarli and the potential of pipeline products further enhance Mirum's outlook and revenue-generating capabilities within the rare disease market.

Mirum Pharmaceuticals faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from potential safety issues and efficacy concerns surrounding its key product, Livmarli, which could impede clinical trial progression and revenue generation. Additionally, the company is experiencing greater-than-expected operating expenses and cash burn, leading to increased reliance on equity issuances that may occur at less favorable valuations. Furthermore, uncertainties regarding regulatory approvals for current and pipeline candidates, coupled with competitive pressures and potential safety signals, further amplify the risks to the company's financial stability and growth projections.